开云app官网登录入口网页版-官方正版

#主要终点#

97篇内容 | 1916人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1997001, encodeId=7d93199e001da, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点, objectType=article, longId=732770, objectId=2432e3277073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2432e3277073, replyNumber=0, likeNumber=81, createdTime=2023-02-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2432e3277073, moduleTitle=Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2432e3277073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996999, encodeId=d234199699980, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=维昇药业宣布其隆培促生长素中国3期临床试验达到主要终点，治疗效果优于生长激素日制剂, objectType=article, longId=727636, objectId=490ee276365c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=490ee276365c, replyNumber=0, likeNumber=93, createdTime=2022-07-01, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=490ee276365c, moduleTitle=维昇药业宣布其隆培促生长素中国3期临床试验达到主要终点，治疗效果优于生长激素日制剂, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=490ee276365c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996996, encodeId=27eb199699670, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点, objectType=article, longId=301019, objectId=aafd3010194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafd3010194a, replyNumber=0, likeNumber=78, createdTime=2022-10-08, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafd3010194a, moduleTitle=Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aafd3010194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=选择性雌激素受体降解剂 (SERD) amcenestrant 治疗乳腺癌，未能达到主要终点, objectType=article, longId=300814, objectId=d3a3300814e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3a3300814e1, replyNumber=0, likeNumber=111, createdTime=2022-08-16, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3a3300814e1, moduleTitle=选择性雌激素受体降解剂 (SERD) amcenestrant 治疗乳腺癌，未能达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d3a3300814e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996997, encodeId=402f199699e9e, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=晚期食管癌一线治疗又添新突破：PD-1单抗「替雷利珠单抗」全球3期临床试验达到主要终点, objectType=article, longId=725482, objectId=de0ae25482c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de0ae25482c5, replyNumber=0, likeNumber=82, createdTime=2022-06-12, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de0ae25482c5, moduleTitle=晚期食管癌一线治疗又添新突破：PD-1单抗「替雷利珠单抗」全球3期临床试验达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=de0ae25482c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996994, encodeId=edc7199699407, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=经先前治疗的严重A型血友病该如何治疗？efanesoctocog alpha在临床试验中已达到主要终点, objectType=article, longId=300734, objectId=5e00300e34a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e00300e34a5, replyNumber=0, likeNumber=101, createdTime=2022-08-09, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e00300e34a5, moduleTitle=经先前治疗的严重A型血友病该如何治疗？efanesoctocog alpha在临床试验中已达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5e00300e34a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996993, encodeId=670f1996993ec, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=礼来的lebrikizumab达到了特应性皮炎研究的主要终点, objectType=article, longId=292567, objectId=27ff29256eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27ff29256eea, replyNumber=0, likeNumber=86, createdTime=2022-06-18, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27ff29256eea, moduleTitle=礼来的lebrikizumab达到了特应性皮炎研究的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27ff29256eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1997002, encodeId=b61f199e00282, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点, objectType=article, longId=732815, objectId=31ade3281512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ade3281512, replyNumber=0, likeNumber=96, createdTime=2022-11-15, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ade3281512, moduleTitle=Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=31ade3281512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996998, encodeId=8ac119969986a, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, objectType=article, longId=726470, objectId=5a4ce2647008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a4ce2647008, replyNumber=0, likeNumber=84, createdTime=2022-08-15, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a4ce2647008, moduleTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5a4ce2647008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1997000, encodeId=33c6199e000ae, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点, objectType=article, longId=728899, objectId=ab8ce28899e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab8ce28899e0, replyNumber=0, likeNumber=74, createdTime=2023-01-09, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab8ce28899e0, moduleTitle=结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ab8ce28899e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996992, encodeId=44e219969928b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Avasopasem治疗放疗诱导的严重口腔粘膜炎，III期ROMAN试验未达到主要终点, objectType=article, longId=218974, objectId=f0e12189e46e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0e12189e46e, replyNumber=0, likeNumber=79, createdTime=2021-12-07, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e12189e46e, moduleTitle=Avasopasem治疗放疗诱导的严重口腔粘膜炎，III期ROMAN试验未达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f0e12189e46e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996990, encodeId=dac1199699022, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, objectType=article, longId=208907, objectId=e5a320890ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a320890ef2, replyNumber=0, likeNumber=63, createdTime=2021-07-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a320890ef2, moduleTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e5a320890ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996988, encodeId=af3619969883c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, objectType=article, longId=208482, objectId=a52b208482ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52b208482ca, replyNumber=0, likeNumber=76, createdTime=2021-03-29, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52b208482ca, moduleTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a52b208482ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996986, encodeId=cde01996986c0, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=重组人GM-CSF治疗COVID-19住院患者，SARPAC临床试验达到了肺功能改善的主要终点, objectType=article, longId=207697, objectId=56f320e69775, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f320e69775, replyNumber=0, likeNumber=76, createdTime=2021-07-20, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f320e69775, moduleTitle=重组人GM-CSF治疗COVID-19住院患者，SARPAC临床试验达到了肺功能改善的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56f320e69775)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996981, encodeId=434819969811b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, objectType=article, longId=204980, objectId=817f204980c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817f204980c0, replyNumber=0, likeNumber=88, createdTime=2021-11-19, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817f204980c0, moduleTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=817f204980c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Mirikizumab达到溃疡性结肠炎研究的主要终点, objectType=article, longId=208618, objectId=b43f20861858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43f20861858, replyNumber=0, likeNumber=75, createdTime=2021-08-07, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43f20861858, moduleTitle=Mirikizumab达到溃疡性结肠炎研究的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b43f20861858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, objectType=article, longId=203284, objectId=ffda20328428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffda20328428, replyNumber=0, likeNumber=65, createdTime=2021-04-12, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffda20328428, moduleTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ffda20328428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996982, encodeId=5fac1996982f5, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, objectType=article, longId=205306, objectId=719320530679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719320530679, replyNumber=0, likeNumber=86, createdTime=2021-09-08, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719320530679, moduleTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=719320530679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996975, encodeId=5c1e19969e51e, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Ibrance联合标准疗法治疗乳腺癌：未达到主要终点, objectType=article, longId=195119, objectId=4c951951194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c951951194a, replyNumber=0, likeNumber=76, createdTime=2020-12-12, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c951951194a, moduleTitle=Ibrance联合标准疗法治疗乳腺癌：未达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4c951951194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996987, encodeId=ab28199698e08, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=NEJM：礼来Aβ抗体二期临床结果公布：达到主要终点，错失次要终点, objectType=article, longId=208386, objectId=c04f20838658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c04f20838658, replyNumber=0, likeNumber=82, createdTime=2021-05-03, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c04f20838658, moduleTitle=NEJM：礼来Aβ抗体二期临床结果公布：达到主要终点，错失次要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c04f20838658)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

主要终点

2020-05-29

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点

2023-02-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

维昇药业宣布其隆培促生长素中国3期临床试验达到主要终点，治疗效果优于生长激素日制剂

2022-07-01

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Fezolinetant治疗中度至重度血管舒缩症状，III期研究未达到主要终点

2022-10-08

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

选择性雌激素受体降解剂 (SERD) amcenestrant 治疗乳腺癌，未能达到主要终点

2022-08-16

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

晚期食管癌一线治疗又添新突破：PD-1单抗「替雷利珠单抗」全球3期临床试验达到主要终点

2022-06-12

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

经先前治疗的严重A型血友病该如何治疗？efanesoctocog alpha在临床试验中已达到主要终点

2022-08-09

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

礼来的lebrikizumab达到了特应性皮炎研究的主要终点

2022-06-18

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点

2022-11-15

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点

2022-08-15

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点

2023-01-09

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Avasopasem治疗放疗诱导的严重口腔粘膜炎，III期ROMAN试验未达到主要终点

2021-12-07

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点

2021-07-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点

2021-03-29

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

重组人GM-CSF治疗COVID-19住院患者，SARPAC临床试验达到了肺功能改善的主要终点

2021-07-20

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点

2021-11-19

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Mirikizumab达到溃疡性结肠炎研究的主要终点

2021-08-07

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点

2021-04-12

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点

2021-09-08

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Ibrance联合标准疗法治疗乳腺癌：未达到主要终点

2020-12-12

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

NEJM：礼来Aβ抗体二期临床结果公布：达到主要终点，错失次要终点

2021-05-03

科室
- - 订阅+
  - 更多科室
工具
服务